Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrevenTRON: Trontinemab in Cognitively Unimpaired Individuals at Risk for Alzheimer's Disease
NCT07717411Phase 3Recruiting
- Sponsor
- Roche
- Start
- Nov 2026
- Primary completion
- Sep 2032
- Countries
- 7
01
Overview
A Phase 3 trial of trontinemab in Alzheimer's disease (AD), sponsored by Roche. Started Nov 2026; status: recruiting.
02
Drugs
trontinemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07717411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07717411.